IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1251-1275 out of 1286.

<< < 46 | 47 | 48 | 49 | 50 | 51 | 52 > >>

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy
Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Cancer
Radiation for prostate cancer linked to secondary cancers, study finds
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.
National Institutes of Health

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without comp
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.

Contact: Laura Sussman
lsussman@mdanderson.org
7-137-452-457-832-264-889
University of Texas M. D. Anderson Cancer Center

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Myriad presents data on BRACAnalysis CDx and HRD at 2014 ASCO meeting
New data presented at ASCO 2014 support the clinical efficacy of Myriad's BRACAnalysis CDx and HRD tests in predicting platinum based therapy response for breast cancer patients. In addition, the company is providing an update on key commercial milestones that underscore its commitment to the field of companion diagnostics. Myriad also will present data on the likely utility of its HRD test as a more comprehensive companion diagnostic for DNA damaging agents.

Contact: Ronald Rogers
rrogers@myriad.com
908-285-0248
Myriad Genetics, Inc.

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Phase I study of DMOT4039A in patients with pancreatic or ovarian cancer
In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 30-May-2014
ASCO 50th Annual Meeting
New drug treatment helps prevent early menopause in breast cancer patients
Among young women treated for breast cancer, one of the most distressing side effects of chemotherapy is early menopause. But a major clinical trial has found that the risk of early menopause can be significantly reduced by adding a drug called goserelin to the chemotherapy regimen. Also, women who took goserelin were more likely to get pregnant and deliver a healthy baby.
NIH/National Cancer Institute

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Stopping statins may benefit terminally ill patients
Results presented today at ASCO 2014 and at the European Association of Palliative Care Research Conference show that stopping statins for cholesterol management in the late stages of cancer or other terminal illnesses may offer quality-of-life and even life-extending benefits. The results highlight the larger question of when, if ever, it is appropriate in patients with life-limiting illnesses to discontinue medications prescribed for other conditions that will likely not lead to their death.
National Institute of Nursing Research

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Study highlights side effects felt by BRCA mutation carriers after cancer risk-reducing procedure
The majority of women with cancer causing BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following prophylactic removal of their Fallopian tubes and ovaries -- a procedure known as risk-reducing salpingo-oophorectomy -- according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania.

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine

Public Release: 30-May-2014
Leukemia
One cell's meat is another cell's poison
The protein JAK2 is of special therapeutic significance: its inactivation is believed to destroy cancer cells. However, the effect of JAK2 inhibition on healthy cells is so far unknown. Scientists at the Vetmeduni Vienna show that the loss of JAK2 causes healthy blood cells to disappear while cancer cells preserve their growth potential. Future studies will reveal whether the findings are going to change treatment in humans. The results were published in the journal Leukemia.

Contact: Veronika Sexl
veronika.sexl@vetmeduni.ac.at
43-664-602-576-291
University of Veterinary Medicine -- Vienna

Public Release: 30-May-2014
Food and Chemical Toxicology
Compounds in saliva and common body proteins may fend off DNA-damaging chemicals
A compound in saliva, along with common proteins in blood and muscle, may protect human cells from powerful toxins in tea, coffee and liquid smoke flavoring, according to results of a new study led by investigators at the Johns Hopkins Kimmel Cancer Center.
NIH/National Cancer Institute

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Hepatitis C reactivation doesn't worsen survival for HIV+ patients diagnosed with lymphoma
Hepatitis C reactivation doesn't worsen survival for HIV+ patients diagnosed with lymphoma.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 30-May-2014
Journal of Clinical Investigation
Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue
Fatigue is a debilitating problem for cancer patients undergoing treatment; however, it also poses a huge detriment after treatment and can significantly affect quality of life. Approximately 30 percent of cancer patients endure persistent fatigue for several years after treatment, according to an American Society of Clinical Oncology Expert Panel co-chaired by Paul Jacobsen, Ph.D., associate center director of Population Sciences at Moffitt Cancer Center.

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 30-May-2014
ASCO 50th Annual Meeting
More patients with ovarian cancer are receiving chemotherapy before surgery
The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Identification of central nervous system involvement for patients with AIDS-related lymphomas
Patients with AIDS-related lymphomas may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 30-May-2014
Nature Biotechnology
New software tool identifies genetic mutations that influence disease risk
Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer.

Contact: Katrina Burton
kburton@mdanderson.org
713-792-8034
University of Texas M. D. Anderson Cancer Center

Public Release: 30-May-2014
Metabolomics
Study explains how green tea could reduce pancreatic cancer risk
New study explains how green tea changed the metabolism of pancreatic cancer cells, opening a new area in cancer-fighting research.
National Institutes of Health, Hirshberg Foundation for Pancreatic Cancer Research

Contact: Laura Mecoy
Lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

Public Release: 30-May-2014
ASCO 50th Annual Meeting
Research shows overall survival benefit for patients with Stage III soft tissue sarcomas
Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 29-May-2014
BJU International
Circumcision linked to reduced risk of prostate cancer in some men
Circumcision is performed for various reasons, including those that are based on religion, aesthetics, or health. New research indicates that the procedure may help prevent prostate cancer in some men. The findings, which are published in BJU International, add to a growing list of advantages to circumcision.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley

Public Release: 29-May-2014
Cancer Cell
Melanoma of the eye caused by 2 gene mutations
Researchers at the University of California, San Diego School of Medicine have identified a therapeutic target for treating the most common form of eye cancer in adults. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug.
National Institutes of Health, California Institute for Regenerative Medicine

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 29-May-2014
Journal of American Society of Nephrology
Reduced kidney function associated with higher risk of renal and urothelial cancer
Researchers who investigated the level of kidney function and subsequent cancer risk in more than one million adults have found that reduced glomerular filtration rate -- a key measure of reduced kidney function and chronic kidney disease -- is an independent risk factor for renal and urothelial cancer but not other cancer types.
National Institutes of Health, NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences

Public Release: 29-May-2014
Journal of the American Society of Nephrology
Reduced kidney function associated with higher risk of renal and urothelial cancer
A key measure of reduced kidney function and chronic kidney disease -- reduced glomerular filtration rate -- is an independent risk factor for renal and urothelial cancer, according to a study published online today in the Journal of the American Society of Nephrology.
National Institutes of Health

Contact: Cyrus Hedayati
chedayati@golinharris.com
415-318-4377
Kaiser Permanente

Public Release: 29-May-2014
Applied Physiology, Nutrition and Metabolism
Diet and exercise in cancer prevention and treatment: Focus of APNM special
This Special Issue titled 'The role of diet, body composition, and physical activity on cancer prevention, treatment, and survivorship' comprises both invited reviews and original papers investigating various themes such as the role of omega-3 fatty acids, amino acids, cancer cachexia, muscle health, exercise training, adiposity and body composition.

Contact: Jenny Ryan
jenny.ryan@nrcresearchpress.com
Canadian Science Publishing (NRC Research Press)

Public Release: 29-May-2014
New England Journal of Medicine
Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.
NIH/National Cancer Institute

Contact: Amanda Harper
amanda.harper2@osumc.edu
614-685-5420
Ohio State University Wexner Medical Center

Public Release: 29-May-2014
PLOS ONE
How breast cancer 'expresses itself'
Two Tel Aviv University researchers have found that 'gene regulation,' the process that shuts off certain parts of a cell's DNA code or blueprint in healthy breast tissue cells, may also play a critical role in the development of breast cancer. Their research proves a significant link between breast-specific genes and the pathology of cancer.

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University

Public Release: 29-May-2014
ASCO 50th Annual Meeting
Rare skin cancer on palms and soles more likely to come back compared to other melanomas
A rare type of melanoma that disproportionately attacks the palms and soles and under the nails of Asians, African-Americans, and Hispanics, who all generally have darker skins, and is not caused by sun exposure, is almost twice as likely to recur than other similar types of skin cancer, according to results of a study in 244 patients.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Showing releases 1251-1275 out of 1286.

<< < 46 | 47 | 48 | 49 | 50 | 51 | 52 > >>

  Search News Releases

     

 

EurekAlert!